Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05809531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05809531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Lead sponsor
Apellis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 29, 2023
Completion date
July 31, 2027
Enrollment
100 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulonephritis, c3 glomerulopathy, c3g, complement 3 glomerulonephritis, complement 3 glomerulopathy, complement 3 glomerulopathy (c3g), ddd, dense deposit disease, ic-mpgn, immune complex membranoproliferative glomerulonephritis (ic-mpgn), membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis (mpgn)